Endocrine Abstracts

Introduction: 131I-Metaiodobenzylguanidine (131I-MIBG) is used as palliative therapy in patients with metastatic neuroendocrine tumours (NET), but can cause bone marrow suppression, hypothyroidism and renal impairment.Methods: Retrospective case note analysis identified 58 patients treated with between May 1996 and May 2006. We assessed the efficacy and toxicity of 131I-MIBG therapy in 49 of these patients (12men; mean age at diagnosis: 57.4 years; range...